跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 301 条关于
“LUGANO”
全部
301
临床试验
184
药物
45
机构
16
资讯
56
去年
EyePoint Pharmaceuticals Doses First Patient in Phase 3 Trial of Duravyu for Wet AMD
13天前
EyePoint's DURAVYU Misses Primary Endpoint in Phase 3 LUGANO Trial for Wet AMD
去年
EYP-1901 Shows Promise in Phase 3 LUGANO Trial for Wet AMD Treatment
去年
EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUGANO Trial of Duravyu for Wet AMD
去年
EyePoint Pharmaceuticals Advances Wet AMD Treatment with Phase 3 Trials
去年
EyePoint's DURAVYU Enters Phase 3 Trial for Wet AMD with First Patient Dosed in LUCIA Study
去年
EYP-1901 Shows Promise in Wet AMD and DME Trials with Significant Reduction in Treatment Burden
去年
EyePoint's DURAVYU Shows Promise in Wet AMD and DME Trials, Anticipates Key Milestones in 2025
去年
EyePoint's EYP-1901 Shows Non-Inferiority to Aflibercept in Wet AMD
去年
LP-168, a Novel BTK Inhibitor, Shows Promise in Relapsed/Refractory Mantle Cell Lymphoma
第 1 页,共 6 页
上一页
下一页